Publication | Open Access
MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
32
Citations
0
References
2019
Year
Pd-1 MabMedicinePharmacologyPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology
No additional data available for this publication yet. Check back later!